Next Article in Journal
Historical H1N1 Influenza Virus Imprinting Increases Vaccine Protection by Influencing the Activity and Sustained Production of Antibodies Elicited at Vaccination in Ferrets
Previous Article in Journal / Special Issue
Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens
Review

Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies

1
Scientist Prophylactic Vaccines Non-Clinical Development, CureVac AG, Paul-Ehrlich-Straße 15, D-72076 Tübingen, Germany
2
Senior Scientist Prophylactic Vaccines Non-Clinical Development, CureVac AG, Paul-Ehrlich-Straße 15, D-72076 Tübingen, Germany
3
Senior Director Prophylactic Vaccines Research, CureVac AG, Paul-Ehrlich-Straße 15, D-72076 Tübingen, Germany
*
Author to whom correspondence should be addressed.
Vaccines 2019, 7(4), 132; https://doi.org/10.3390/vaccines7040132
Received: 13 August 2019 / Revised: 15 September 2019 / Accepted: 19 September 2019 / Published: 27 September 2019
(This article belongs to the Special Issue RNA Vaccines)
There is a global need for effective and affordable rabies vaccines, which is unmet by current vaccines due to limitations in their production capacities, required administration schedules, storage requirements, and cost. Many different experimental approaches previously used for bacterial and viral vaccines have been applied to rabies, but with variable success. One of the most promising new concepts is the use of messenger RNA (mRNA) in encoding the main rabies virus antigen, the envelope glycoprotein (RABV-G). CureVac has applied their proprietary technology platform for the production of mRNA to this problem, resulting in the rabies vaccine candidate CV7201. Following preclinical studies in mice and pigs showing that CV7201 could induce neutralizing immune responses that protected against rabies virus, different dosages and routes of administration of CV7201 were tested in a phase 1 human study. This clinical study proved that mRNA vaccination was safe and had an acceptable reactogenicity profile, but immune responses depended on the mode of administration, and they did not unequivocally support CV7201 for further development as a prophylactic vaccine with this particular formulation. Further, preclinical studies using RABV-G mRNA encapsulated in lipid nanoparticles (LNPs) showed an improved response in both mice and nonhuman primates, and these encouraging results are currently being followed up in clinical studies in humans. This review summarizes the recent advances in mRNA vaccines against rabies. View Full-Text
Keywords: rabies vaccines; mRNA vaccines; lipid nanoparticles rabies vaccines; mRNA vaccines; lipid nanoparticles
Show Figures

Figure 1

MDPI and ACS Style

Armbruster, N.; Jasny, E.; Petsch, B. Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies. Vaccines 2019, 7, 132. https://doi.org/10.3390/vaccines7040132

AMA Style

Armbruster N, Jasny E, Petsch B. Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies. Vaccines. 2019; 7(4):132. https://doi.org/10.3390/vaccines7040132

Chicago/Turabian Style

Armbruster, Nicole, Edith Jasny, and Benjamin Petsch. 2019. "Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies" Vaccines 7, no. 4: 132. https://doi.org/10.3390/vaccines7040132

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop